M&A / Deals LEO Pharma to acquire gene therapy company Replay Pharmaceutical Business ReviewThe acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector.Gene Therapy PlatformRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. Gene Therapy Platform Read full story Post navigation Previous: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant openingNext: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
